API | buthionine sulfoximine

buthionine sulfoximine Report issue

Small molecule Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Buthionine sulfoximine (BSO) is a sulfoximine derivative which reduces levels of glutathione and is being investigated as an adjunct with chemotherapy in the treatment of cancer. The compound inhibits gamma-glutamylcysteine synthetase, the enzyme required in the first step of glutathione synthesis. Buthionine sulfoximine may also be used to increase the sensitivity of parasites to oxidative antiparasitic drugs. ^Wikipedia

Chemistry

SMILES: CCCC[S+](=N)([O-])CC[C@H](N)C(=O)O
InChIKey: WDFRNLYXRQXXFS-CVSPRKDYSA-N
Mol. Mass: 222.31
ALogP: 0.64 Partition coefficient
ChEMBL Molecule:
buthionine sulfoximine

More Chemistry

Pharmacology

Mechanism of Action:
- Glutamate--cysteine ligase catalytic subunit (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

buthionine sulfoximine

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Melanoma (Phase 1)

Neuroblastoma (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 3
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue